Impact of CYP3A5 genotype of recipients as well as donors on the tacrolimus pharmacokinetics and infectious complications after living-donor liver transplantation for Japanese adult recipients

Annals of Transplantation

Volumn 16, Issue 4, 2011, Pages 55-62

  Muraki, Yuichi ^a   Usui, Masanobu ^b   Isaji, Shuji ^b   Mizuno, Shugo ^b   Nakatani, Kaname ^b   Yamada, Tomomi ^b   Iwamoto, Takuya ^a   Uemoto, Shinji ^c   Nobori, Tsutomu ^b   Okuda, Masahiro ^a  

^a MIE UNIVERSITY HOSPITAL   (Japan)

^b MIE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

CYP3A5; Liver transplantation; Pharmacokinetics; Single nucleotide polymorphism; Tacrolimus

Indexed keywords

CYTOCHROME P450 3A5; TACROLIMUS;

ADULT; AGED; ARTICLE; DONOR; DRUG BLOOD LEVEL; FEMALE; GENE EXPRESSION; GENOTYPE; GRAFT RECIPIENT; HUMAN; INFECTIOUS COMPLICATION; JAPANESE; LIVER TRANSPLANTATION; LIVING DONOR; MAJOR CLINICAL STUDY; MALE; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 84855502073     PISSN: 14259524     EISSN: None     Source Type: Journal    
DOI: 10.12659/AOT.882219     Document Type: Article

References (19)

1. Denton MD, Magee CC, Sayegh MH: Immunosuppressive strategies in transplantation. Lancet, 1999; 353: 1083-91
2. Fredericks S, Holt DW, MacPhee IA: The pharmacogenetics of immunosuppression for organ transplantation: a route to individualization of drug administration. Am J Pharmacogenomics, 2003; 3: 291-301
3. Clase CM, Mahalati K, Kiberd BA et al: Adequate early cyclosporin exposure is critical to prevent renal allograft rejection: patients monitored by absorption profiling. Am J Transplant, 2002; 2: 789-95
4. Macphee IA, Holt DW: A Pharmacogenetic Strategy for Immunosuppression Based on the CYP3A5 Genotype. Transplantation, 2008; 85: 163-65
5. Kuehl P, Zhang J, Lin Y et al: Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet, 2001; 27: 383-91
6. Uesugi M, Masuda S, Katsura T et al: Effect of intestinal CYP3A5 on postoperative tacrolimus trough levels in living-donor liver transplant recipients. Pharmacogenet Genomics, 2006; 16: 119-27
7. Wei-lin W, Jing J, Shu-sen Z et al: Tacrolimus dose requirement in relation to donor and recipient ABCB1 and CYP3A5 gene polymorphisms in Chinese liver transplant patients. Liver Transpl, 2006; 12: 775-80
8. Yu S, Wu L, Jin J et al: Influence of CYP3A5 gene polymorphisms of donor rather than recipient to tacrolimus individual dose requirement in liver transplantation. Transplantation, 2006; 81: 46-51
9. Macphee IA, Fredericks S, Mohamed M et al: Tacrolimus pharmacogenetics: the CYP3A5*1 allele predicts low dose-normalized tacrolimus blood concentrations in whites and South Asians. Transplantation, 2005; 79: 499-502
10. Hesselink DA, van Schaik RH, van der Heiden IP et al: Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. Clin Pharmacol Ther, 2003; 74: 245-54
11. Tsuchiya N, Satoh S, Tada H et al: Influence of CYP3A5 and MDR1 (ABCB1) polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients. Transplantation, 2004; 78: 1182-87
12. Zhang X, Liu ZH, Zheng JM et al: Influence of CYP3A5 and MDR1 polymorphisms on tacrolimus concentration in the early stage after renal transplantation. Clin Transplant, 2005; 19: 638-43
13. Kuypers DR, de Jonge H, Naesens M et al: CYP3A5 and CYP3A4 but not MDR1 single-nucleotide polymorphisms determine long-term tacrolimus disposition and drug-related nephrotoxicity in renal recipients. Clin Pharmacol Ther, 2007; 82: 711-25
14. Mizuno S, Hamada T, Nakatani K et al: Monitoring peripheral blood CD4+ adenosine triphosphate activity after living donor liver transplantation: impact of combination assays of immune function and CYP3A5 genotype. J Hepatobiliary Pancreat Sci, 2011; 18(2): 226-32; discussion 232-34
15. Fukuen S, Fukuda T, Maune H et al: Novel detection assay by PCR-RFLP and frequency of the CYP3A5 SNPs, CYP3A5*3 and *6, in a Japanese population. Pharmacogenetics, 2002; 12: 331-34
16. Hiratsuka M, Takekuma Y, Endo N et al: Allele and genotype frequencies of CYP2B6 and CYP3A5 in the Japanese population. Eur J Clin Pharmacol, 2002; 58: 417-21
17. Saeki M, Saito Y, Nakamura T et al: Single nucleotide polymorphisms and haplotype frequencies of CYP3A5 in a Japanese population. Hum Mutat, 2003; 21: 653
18. Fukudo M, Yano I, Yoshimura A et al: Impact of MDR1 and CYP3A5 on the oral clearance of tacrolimus and tacrolimus-related renal dysfunction in adult living-donor liver transplant patients. Pharmacogenet Genomics, 2008; 18: 413-23
19. Shimomura M, Masuda S, Goto M et al: Required transient dose escalation of tacrolimus in living-donor liver transplant recipients with high concentrations of a minor metabolite M-II in bile. Drug Metab Pharmacokinet, 2008; 23: 313-17